Psychomotor retardation in depression: Biological underpinnings, measurement, and treatment.

16:21 EST 22nd December 2014 | BioPortfolio

Summary of "Psychomotor retardation in depression: Biological underpinnings, measurement, and treatment."

Psychomotor retardation is a long established component of depression that can have significant clinical and therapeutic implications for treatment. Due to its negative impact on overall function in depressed patients, we review its biological correlates, optimal methods of measurement, and relevance in the context of therapeutic interventions. The aim of the paper is to provide a synthesis of the literature on psychomotor retardation in depression with the goal of enhanced awareness for clinicians and researchers. Increased knowledge and understanding of psychomotor retardation in major depressive disorder may lead to further research and better informed diagnosis in regards to psychomotor retardation. Manifestations of psychomotor retardation include slowed speech, decreased movement, and impaired cognitive function. It is common in patients with melancholic depression and those with psychotic features. Biological correlates may include abnormalities in the basal ganglia and dopaminergic pathways. Neurophysiologic tools such as neuroimaging and transcranial magnetic stimulation may play a role in the study of this symptom in the future. At present, there are three objective scales to evaluate psychomotor retardation severity. Studies examining the impact of psychomotor retardation on clinical outcome have found differential results. However, available evidence suggests that depressed patients with psychomotor retardation may respond well to electroconvulsive therapy (ECT). Current literature regarding antidepressants is inconclusive, though tricyclic antidepressants may be considered for treatment of patients with psychomotor retardation. Future work examining this objective aspect of major depressive disorder (MDD) is essential. This could further elucidate the biological underpinnings of depression and optimize its treatment.

Affiliation

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Journal Details

This article was published in the following journal.

Name: Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Pages: 395-409

Links

PubMed Articles [26829 Associated PubMed Articles listed on BioPortfolio]

Psychomotor agitation in major depressive disorder is a predictive factor of mood-switching.

The relationship between psychomotor agitation in unipolar depression and mood-switching from depression to manic, hypomanic and mixed states has been controversial. We investigated the future risk of...

Polymicrogyria, Large Corpus Callosum and Psychomotor Retardation in Four-Year-Old Girl: Potential Association Based on MR Findings. A Case Report and Literature Review.

SUMMARY - We describe a child from consanguineous parents presenting mega corpus callosum (MegaCC), polymicrogyria, psychomotor retardation with swallowing difficulties and language impairment perhaps...

Psychomotor Retardation, Attention Deficit and Executive Dysfunctional in Young Non-hospitalised Un-medicated Non-psychotic Unipolar Depression Patients.

Background: Neuropsychological deficits have been reported in patients with Major Depressive Disorder (MDD) during an acute episode. The reaction time gives an idea about integrity and the processing ...

Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial.

In a randomized, controlled trial (n = 30), we showed that botulinum toxin injection to the glabellar region produces a marked improvement in the symptoms of major depression. We hypothesized that...

Retardation of psychomotor development and tremor in a boy with 48,XXYY karyotype.

We report a seven-year-old boy with 48,XXYY karyotype, presenting with tremor and a slight retardation of psychomotor development. Although the physical phenotype is similar to 47,XXY, 48,XXYY is asso...

Clinical Trials [2873 Associated Clinical Trials listed on BioPortfolio]

A Study of GW856553X For the Treatment of Depression

GW856553 is a novel compound, currently in development for the treatment of Major Depressive Disorder (MDD), and other indications. GW856553 inhibits a protein which is responsible for the...

Determinants in Antidepressant Outcomes

This study is designed to understand if a biological measurement, of how platelets respond to serotonin (a chemical in the blood sometimes referred to as SERT), can provide information tha...

Safety and Efficacy of BMMNCin Patients With Mental Retardation

Mental retardation is a condition diagnosed before age 18 that includes below-average general intellectual function, and a lack of the skills necessary for daily living. Mental retardation...

Riluzole to Treat Depression in Bipolar Disorder

This study examines if Riluzole, (FDA approved for ALS), will improve symptoms of depression in Bipolar Disorder. Pupose: This study will examine the safety and effectiveness of riluzole...

Treatment of Psychotic Major Depression With Mifepristone

The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treati...

Medical and Biotech [MESH] Definitions

An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)

An autosomal recessive neurodegenerative disorder caused by the absence or deficiency of BETA-GALACTOSIDASE. It is characterized by intralysosomal accumulation of G(M1) GANGLIOSIDE and oligosaccharides, primarily in neurons of the central nervous system. The infantile form is characterized by MUSCLE HYPOTONIA, poor psychomotor development, HIRSUTISM, hepatosplenomegaly, and facial abnormalities. The juvenile form features HYPERACUSIS; SEIZURES; and psychomotor retardation. The adult form features progressive DEMENTIA; ATAXIA; and MUSCLE SPASTICITY. (From Menkes, Textbook of Child Neurology, 5th ed, pp96-7)

Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from BIOLOGICAL FACTORS in that the latter are compounds with biological or physiological activity made by living organisms. (From Webster's 3d ed)

A clinically recognized malformation condition caused by a distal 11q deletion. The features of the syndrome are growth retardation, psychomotor retardation, trigonocephaly, divergent intermittent strabismus, epicanthus, telecanthus, broad nasal bridge, short nose with anteverted nostrils, carp-shaped upper lip, retrognathia, low-set dysmorphic ears, bilateral camptodactyly, and hammertoes. Most patients have a THROMBOCYTOPENIA and platelet dysfunction known also as Paris-Trousseau type thrombocytopenia.

Decompression external to the body, most often the slow lessening of external pressure on the whole body (especially in caisson workers, deep sea divers, and persons who ascend to great heights) to prevent DECOMPRESSION SICKNESS. It includes also sudden accidental decompression, but not surgical (local) decompression or decompression applied through body openings.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Public Health
Latest News Clinical Trials Research Drugs Reports Corporate
Public health is the scientific, political and sociological approach by a society to maximise the health of the population through disease preventaion and mainenance of healthy life-styles. The mains areas of public health are epidemiology, biostatistics...

Advertisement